当前位置:
X-MOL 学术
›
J. Hepatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Reply to “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?”
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-11-08 , DOI: 10.1016/j.jhep.2024.11.004 Moon Haeng Hur, Jeong-Hoon Lee
中文翻译:
回复 “预测慢性乙型肝炎功能治愈后肝脏相关结果的机器学习模型:肝硬化是性能驱动吗?
这项工作得到了韩国科学和信息通信技术部 (S0252-21-1001)、作为生物未来战略研究项目一部分的韩国肝脏研究基金会和首尔国立大学医院研究基金 (04-2019-3090) 资助的国家 IT 产业促进局赠款的支持。
MH 和 JL 均平等地起草和审查了这封信
Moon Haeng Hur:没什么好宣布的;Jeong-Hoon Lee:Jeong-Hoon Lee 获得了 Yuhan Pharmaceuticals 和 GreenCross Cell 的研究资助,以及 Samil Pharmaceuticals、GreenCross Cell、Daewoong Pharmaceuticals 和 Gilead Korea 的讲座费。
更新日期:2024-11-09
Journal of Hepatology ( IF 26.8 ) Pub Date : 2024-11-08 , DOI: 10.1016/j.jhep.2024.11.004 Moon Haeng Hur, Jeong-Hoon Lee
Section snippets
Grant support
This work was supported by National IT Industry Promotion Agency grant funded by the Korea Ministry of Science and ICT (S0252-21-1001), Liver Research Foundation of Korea as part of Bio Future Strategies Research Project, and Seoul National University Hospital Research Fund (04-2019-3090).Authors’ contributions
MH and JL both drafted and reviewed the letter equallyDeclaration of Competing Interest
Moon Haeng Hur: Nothing to declare; Jeong-Hoon Lee: Jeong-Hoon Lee receives research grants from Yuhan Pharmaceuticals and GreenCross Cell, and lecture fees from Samil Pharmaceuticals, GreenCross Cell, Daewoong Pharmaceuticals, and Gilead Korea.中文翻译:
回复 “预测慢性乙型肝炎功能治愈后肝脏相关结果的机器学习模型:肝硬化是性能驱动吗?
部分片段
资助支持
这项工作得到了韩国科学和信息通信技术部 (S0252-21-1001)、作为生物未来战略研究项目一部分的韩国肝脏研究基金会和首尔国立大学医院研究基金 (04-2019-3090) 资助的国家 IT 产业促进局赠款的支持。
作者的贡献
MH 和 JL 均平等地起草和审查了这封信
利益争夺声明
Moon Haeng Hur:没什么好宣布的;Jeong-Hoon Lee:Jeong-Hoon Lee 获得了 Yuhan Pharmaceuticals 和 GreenCross Cell 的研究资助,以及 Samil Pharmaceuticals、GreenCross Cell、Daewoong Pharmaceuticals 和 Gilead Korea 的讲座费。